Lv11
86 积分 2022-09-19 加入
IgA肾病的治疗进展
1小时前
已关闭
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
21天前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
21天前
已完结
Tolerogenic Dendritic Cells in Transplantation: From Preclinical to Clinical Application
1个月前
已完结
Telitacicept: First Approval
2个月前
已完结
Optimizing outcome in SLE: treating-to-target and definition of treatment goals
2个月前
已完结
Understanding B‐cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B‐cell immunomics approach
2个月前
已完结
Systemic lupus erythematosus
2个月前
已完结
B-cell depletion in the treatment of lupus nephritis
2个月前
已完结
Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before–after trial
2个月前
已完结
皖公网安备34019202002308
